Actively Recruiting
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
Led by Samsung Medical Center · Updated on 2025-06-26
200
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and high risk of heart failure, and its mechanism. For this reason, we compared cardiac magnetic resonance imaging (CMR) parameters and clinical outcomes between the SGLT-2 inhibitor group and the control group to confirm the efficacy and safety of SGLT-2 inhibitors.
CONDITIONS
Official Title
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be at least 18 years old
- Able to understand risks, benefits, and alternatives and provide written informed consent
- Diagnosed with Type 1 myocardial infarction (STEMI or NSTEMI) confirmed by cardiac troponin levels and symptoms or ECG changes
- At high risk of heart failure, defined as having a left ventricular ejection fraction below 50% or symptoms/signs of pulmonary congestion requiring treatment
You will not qualify if you...
- Target lesion unsuitable for PCI as decided by the operator
- Required cardiopulmonary resuscitation due to cardiac arrest before randomization
- Rescue PCI after thrombolysis or facilitated PCI
- History of previous myocardial infarction
- History of heart failure
- Previous use of SGLT-2 inhibitors
- Glomerular filtration rate below 30 ml/min/1.73m2 or on dialysis
- Type 1 diabetes mellitus
- Known allergy or contraindication to SGLT-2 inhibitors
- Pregnant or breastfeeding women
- Non-cardiac conditions with life expectancy less than 1 year or likely to prevent study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea
Actively Recruiting
Research Team
Y
Young Bin Song, MD, PhD
CONTACT
K
Ki Hong Choi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here